GSK
3 years ago ⋅ English ⋅ 13 min read
Newsroom
GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA

For media and investors only- New data evaluating Blenrep (belantamab mafodotin) in combination with standard of care and investigational multiple myeloma therapies to be presented- Lon... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director

GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr Vishal Sikka, founder and CEO of Vianai Systems, will join the Board of the Company as a Non-Executive Director. He will... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea

For media and investors onlyIssued: Sungnam, South Korea, and London, UK- Recombinant protein-based ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising ti... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER

GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CERFor media and investors onlyFull... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
US Food and Drug Administration accepts New Drug Application for daprodustat

For media and investors only- Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five tri... Read More
GSK
3 years ago ⋅ English ⋅ 11 min read
Newsroom
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn

For media and investors onlyIssued: 13 April 2022, London UK- Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofi... Read More